Comment from Alliance for Regenerative Medicine (ARM)

Summary: The Alliance for Regenerative Medicine (ARM) supports the FDA's draft guidance on the safety assessment of genome editing in human gene therapy products. They recommend refining the guidance to ensure it remains risk-based, modality-specific, and proportionate to the biological risk of different editing technologies.